Fluphenazine: A Comprehensive Pharmacological and Clinical Monograph

I. Executive Summary

Fluphenazine is a high-potency, first-generation (typical) antipsychotic agent belonging to the propylpiperazine subclass of phenothiazines.[1] First introduced into clinical practice in 1959, it has historically served as a foundational treatment for the management of chronic psychotic disorders, most notably schizophrenia.[1] The therapeutic efficacy of Fluphenazine is primarily derived from its potent antagonism of post-synaptic dopamine D2 receptors within the brain's mesolimbic pathway, a mechanism that effectively targets the positive symptoms of psychosis, such as hallucinations and delusions.[1]

Despite its established efficacy, which is comparable to that of low-potency antipsychotics, the clinical utility of Fluphenazine is significantly constrained by a pronounced liability for inducing severe and potentially irreversible neurological side effects.[1] These include a high incidence of acute extrapyramidal symptoms (EPS), such as dystonia and akathisia, and the long-term risk of tardive dyskinesia (TD).[1] This challenging safety profile has led to a substantial decline in its use following the development of atypical (second-generation) antipsychotics, which offer a more favorable neurological tolerability.[2]

Fluphenazine is available in multiple formulations, including oral tablets, an oral elixir, an oral concentrate, and a short-acting intramuscular injection (as the hydrochloride salt). Critically, it is also available as a long-acting injectable (LAI) depot formulation (as the decanoate ester), which provides a therapeutic effect for up to four weeks per administration.[1] This LAI formulation secures a contemporary niche for Fluphenazine in the maintenance therapy of patients with chronic schizophrenia who have a history of poor adherence to oral medication regimens.[2]

A paramount safety concern associated with Fluphenazine, and all antipsychotics, is a black-box warning from the U.S. Food and Drug Administration (FDA) regarding an increased risk of mortality in elderly patients with dementia-related psychosis.[2] Consequently, its use is contraindicated in this vulnerable population. While Fluphenazine remains available as a generic medication in many countries and its injectable form is on the World Health Organization's List of Essential Medicines, its brand-name versions have been discontinued in major markets, and the drug has been withdrawn entirely in others, including Australia, presenting significant challenges for legacy patients stabilized on the therapy.[1]

II. Drug Identification and Physicochemical Properties

This section establishes the foundational identity of Fluphenazine, linking its chemical structure to its physical properties, which are crucial for formulation development and for understanding its behavior in biological systems.

Nomenclature and Classification

• Generic Name: Fluphenazine.[1]
• Drug Class: Fluphenazine is classified as a first-generation, or typical, antipsychotic. Chemically, it is a derivative of phenothiazine, belonging to the potent propylpiperazine subclass.[1]
• Synonyms and Brand Names: Historically, Fluphenazine was marketed under numerous brand names, including Prolixin®, Permitil®, Modecate®, and Moditen®.[1] While many of these brand-name products have been discontinued in markets such as the United States, generic formulations remain available.[10]
• IUPAC Name: The systematic chemical name for Fluphenazine is 2-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol.[1]
• Chemical Definition: Structurally, Fluphenazine is defined as a 10H-phenothiazine molecule substituted with a trifluoromethyl group at the 2-position of the phenothiazine nucleus and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl side chain at the N-10 position.[3] This trifluoromethyl group distinguishes it from other propylpiperazine derivatives like perphenazine and contributes to its high potency.[8]

Chemical Structure and Properties

• Molecular Formula: $C_{22}H_{26}F_{3}N_{3}OS$.[1]
• Molar Mass: 437.53 g·mol−1.[1]
• Structural Identifiers:
• CAS Number: 69-23-8.[1]
• SMILES: FC(F)(F)c2cc1N(c3c(Sc1cc2)cccc3)CCCN4CCN(CCO)CC4.[1]
• InChIKey: PLDUPXSUYLZYBN-UHFFFAOYSA-N.[1]

A consolidated table of identifiers is essential for a reference monograph, allowing researchers and clinicians to cross-reference the compound across multiple international databases, facilitating further investigation and ensuring unambiguous identification.

Identifier Type	Identifier Code	Source
DrugBank ID	DB00623	1
CAS Number	69-23-8	1
PubChem CID	3372	1
IUPHAR/BPS	204	1
ChemSpider	3255	1
UNII	S79426A41Z	1
KEGG	D07977	1
ChEBI	CHEBI:5123	1
ChEMBL	CHEMBL726	1

Physicochemical Properties

• Physical Form: In its base form, Fluphenazine is described as a solid and, more specifically, as a dark brown viscous oil.[16] Its dihydrochloride salt, commonly used in oral formulations, forms white crystals.[3] The decanoate ester, used in the long-acting injection, is a pale yellow-orange, viscous liquid that may slowly crystallize at room temperature.[16]
• Solubility: Fluphenazine is poorly soluble in water, with an aqueous solubility of approximately 31.1 mg/L at 37 °C.[16] This low aqueous solubility is a key factor influencing its oral bioavailability and the design of its formulations.
• Lipophilicity (LogP): The octanol-water partition coefficient (logP) is reported as 4.36, indicating that Fluphenazine is a highly lipophilic compound.[16]
• Stability: The esterified forms of Fluphenazine, such as the decanoate and enanthate, are noted to be sensitive to light and should be protected from it.[16]
• Decomposition: When subjected to high heat, Fluphenazine decomposes to emit highly toxic fumes containing hydrogen fluoride, nitrogen oxides, and sulfur oxides, which is reflective of its elemental composition.[3]

A direct and critical link exists between Fluphenazine's physicochemical properties and its available clinical formulations. Its high lipophilicity (logP 4.36) and poor water solubility are the primary drivers of its very low oral bioavailability, which is reported to be only 2.7%.[1] This is due to poor dissolution in the gastrointestinal tract and significant first-pass metabolism in the liver. At the same time, these very properties make Fluphenazine an ideal candidate for a long-acting injectable (LAI) depot formulation. The creation of an even more lipophilic prodrug, the decanoate ester (with a calculated logP of approximately 8.22), allows the drug to be suspended in a sesame oil vehicle.[18] When injected intramuscularly or subcutaneously, this oil-based depot creates a reservoir from which the highly lipophilic drug ester slowly partitions into the surrounding aqueous biological environment, is hydrolyzed back to the active Fluphenazine moiety, and enters the systemic circulation. This process of slow release provides a sustained therapeutic effect that can last for up to four weeks or longer from a single injection.[1] Thus, the drug's primary disadvantage in oral formulation (poor solubility) is strategically leveraged as a key advantage for creating a highly effective LAI, which is crucial for managing the common clinical challenge of medication non-adherence in patients with schizophrenia.

III. Clinical Pharmacology

This section deconstructs the interactions of Fluphenazine with the body, from its molecular targets to its absorption, distribution, metabolism, and excretion. A thorough understanding of these pharmacological principles is fundamental to comprehending its therapeutic effects and its extensive adverse effect profile.

Mechanism of Action

• Primary Mechanism: The antipsychotic effect of Fluphenazine is primarily attributed to its potent, post-synaptic antagonism of dopamine D2 receptors.[1] This blockade occurs in multiple dopaminergic pathways in the brain, but its therapeutic action against the "positive" symptoms of schizophrenia (e.g., hallucinations, delusions, disorganized thought) is believed to result from D2 receptor blockade in the mesolimbic and cortical pathways.[2]
• Other Receptor Activity: In addition to its primary action on D2 receptors, Fluphenazine also blocks dopamine D1 receptors.[4] Its pharmacological activity extends to depressing the release of various hypothalamic and hypophyseal hormones, an action mediated by dopamine blockade in the tuberoinfundibular pathway, which contributes significantly to its endocrine side effect profile.[4] Furthermore, its effects on the reticular activating system are thought to influence wakefulness and mediate its antiemetic properties.[4]
• Additional Cellular Effects: At a cellular level, Fluphenazine has been demonstrated to inhibit the polymerization of tubulin.[1] This property is shared with other phenothiazine derivatives, though its clinical relevance to the antipsychotic or adverse effects of the drug is less well-characterized compared to its well-established receptor-blocking activities.

Pharmacodynamics (Receptor Binding Profile)

Fluphenazine exhibits a broad, or "promiscuous," receptor binding profile, acting as an antagonist at multiple neurotransmitter receptor types. This lack of receptor selectivity is characteristic of first-generation antipsychotics and is the underlying reason for its wide array of both therapeutic and adverse effects.[1]

• High-Affinity Targets: Fluphenazine demonstrates very high binding affinity (indicated by low nanomolar Ki values) for several key receptors. Its potent antagonism at Dopamine D2 receptors (Ki 0.89 nM) and D3 receptors (Ki 1.412 nM) confirms its status as a high-potency antipsychotic agent.[1] It also binds with high affinity to several serotonin receptors, including 5-HT2A (Ki 3.8 nM), 5-HT6 (Ki 7.9 nM), and 5-HT7 (Ki 8 nM), as well as to Alpha-1A Adrenergic receptors (Ki 6.4 nM).[1]
• Moderate to Low Affinity Targets: The drug possesses weaker, but still clinically significant, antagonistic activity at Histamine H1 and Muscarinic M1 receptors.[1] This pharmacodynamic fingerprint explains why Fluphenazine produces weaker sedative and anticholinergic effects compared to low-potency phenothiazines like chlorpromazine, which have much higher affinity for H1 and M1 receptors.[8]

The quantitative receptor binding profile of Fluphenazine provides a direct, evidence-based correlation between its molecular targets and its observed clinical outcomes. The very low Ki value at the D2 receptor explains its potent antipsychotic efficacy but also its high propensity for causing movement disorders (EPS) and hyperprolactinemia through D2 blockade in the nigrostriatal and tuberoinfundibular pathways, respectively. Similarly, its high affinity for the α1A adrenergic receptor is the direct cause of its potential to induce orthostatic hypotension, while its moderate affinity for the H1 receptor accounts for its sedative properties.

Receptor Target	Binding Affinity (Ki, nM)	Action	Source
Dopamine D2	0.89	Antagonist	1
Dopamine D3	1.412	ND	1
Dopamine D1	14.45	Antagonist	1
Dopamine D4	89.12	ND	1
Serotonin 5-HT2A	3.8–98	Antagonist	1
Serotonin 5-HT6	7.9–38	ND	1
Serotonin 5-HT7	8	ND	1
Adrenergic α1A	6.4–9	Antagonist	1
Histamine H1	7.3–70	Antagonist	1
Muscarinic M1	>1000	Antagonist	1

(ND: Not determined in the source material)

Pharmacokinetics

• Absorption: When administered orally, Fluphenazine is rapidly absorbed, with peak plasma concentrations ($C_{max}$) reached approximately 2 hours after ingestion.[1] However, its oral bioavailability is exceptionally low, estimated at only 2.7%.[1] This is a result of poor dissolution due to its low aqueous solubility and, more significantly, extensive pre-systemic (first-pass) metabolism in the liver.[1]
• Distribution: Following absorption, Fluphenazine exhibits considerable inter-individual variability in steady-state plasma concentrations.[1] This suggests that genetic and environmental factors influencing absorption, metabolism, or excretion play a significant role in determining drug exposure for a given dose.
• Metabolism: While the complete metabolic pathways of Fluphenazine are described as "unclear," it is firmly established that it is a major substrate of the cytochrome P450 2D6 (CYP2D6) enzyme system.[1] It also functions as a weak inhibitor of the CYP2C9 and CYP2E1 isoenzymes.[2] Other metabolic routes, such as glucuronidation and oxidation, have also been mentioned.[17]
• Elimination: The elimination of Fluphenazine and its metabolites occurs through both urine and feces.[1] The elimination half-life ($t_{1/2}$) is highly dependent on the formulation administered:
• Oral (HCl): Approximately 15–16 hours.[1]
• Intramuscular (HCl, short-acting): Approximately 15 hours.[1]
• Intramuscular/Subcutaneous (Decanoate, long-acting): 7–10 days, reflecting the slow, rate-limiting release of the drug from the oil-based depot injection site.[1]

The combination of Fluphenazine's primary metabolism by the highly polymorphic CYP2D6 enzyme, its narrow therapeutic window, and its severe, dose-dependent side effects creates a significant clinical imperative for personalized medicine.[2] The gene encoding for CYP2D6 has numerous allelic variants, leading to distinct patient phenotypes: poor, intermediate, extensive (normal), and ultra-rapid metabolizers. A patient who is a CYP2D6 "poor metabolizer" will have markedly reduced capacity to clear Fluphenazine, leading to significantly higher plasma concentrations from a standard dose. This effectively results in an overdose, dramatically increasing the risk of severe EPS, acute dystonia, and potentially neuroleptic malignant syndrome. Conversely, co-administration of a potent CYP2D6 inhibitor (such as the antidepressants fluoxetine or bupropion) can phenocopy this genetic state, while a CYP2D6 inducer could lead to sub-therapeutic levels and treatment failure. Therefore, prescribing a narrow therapeutic index drug like Fluphenazine without careful consideration of the patient's metabolic status—either through pharmacogenomic testing or, at a minimum, a thorough screening for interacting co-medications—constitutes a significant and preventable clinical risk.

IV. Clinical Applications and Efficacy

This section outlines the established clinical uses of Fluphenazine, distinguishing between officially approved indications and other applications based on clinical experience and investigation.

Approved Indications (FDA)

• The primary FDA-approved indication for Fluphenazine is the symptomatic management of manifestations of psychotic disorders, with a specific focus on schizophrenia.[2] It is effective in targeting the positive symptoms of the illness, such as hallucinations, delusions, and disorganized speech.[2]
• The long-acting decanoate injectable formulation is specifically indicated for the long-term maintenance therapy of patients with chronic schizophrenia who require prolonged parenteral neuroleptic treatment.[2] This formulation is particularly valuable for patients who have demonstrated poor or unreliable adherence to daily oral medication, a common challenge in this patient population.[2]
• It is explicitly noted in regulatory documents that Fluphenazine has not been shown to be effective in the management of behavioral complications in patients with intellectual disabilities (formerly referred to as mental retardation).[4]

Off-Label and Investigational Uses

Beyond its primary approved use, Fluphenazine has been employed in several off-label clinical scenarios:

• Movement Disorders: Due to its potent dopamine-blocking effects, Fluphenazine has been used off-label to manage the hyperkinetic movements (chorea) associated with Huntington's disease and to suppress motor and phonic tics in patients with chronic tic disorders, including Tourette syndrome.[2]
• Mood Disorders: While not FDA-approved for this purpose, Fluphenazine has been used off-label in the management of bipolar disorder, typically for the short-term control of acute manic episodes or for treating psychotic features that can accompany mania or depression.[2]
• Other Psychiatric Conditions: Off-label use has also been reported for the management of generalized behavioral disturbances and impulse control disorders, although evidence for these uses is limited.[22]
• Investigational Use: A completed Phase 2 clinical trial (NCT00929578) explored the use of Fluphenazine Hydrochloride for the treatment of psoriasis.[27] This suggests a potential, though not well-characterized, immunomodulatory or anti-inflammatory role for the drug that falls outside its known neuropsychiatric mechanisms.

Summary of Clinical Trial Evidence

The provided documentation references several clinical trials that help to contextualize Fluphenazine's efficacy and role in treatment.

• Schizophrenia: Fluphenazine was included as a potential treatment option in a clinical trial (NCT02600741) investigating family intervention strategies in recent-onset schizophrenia, reflecting its continued relevance as a standard therapy in research settings.[28]
• Metabolic Effects: Its inclusion in a study (NCT02582736) examining the risk of hyperglycemic emergencies across various antipsychotics underscores the recognized metabolic risks associated with this class of drugs, even for first-generation agents.[29]
• Efficacy vs. Placebo and Other Antipsychotics: Clinical evidence supports that Fluphenazine is more effective than placebo in reducing relapse rates in schizophrenia, though this benefit comes at the cost of a high burden of extrapyramidal side effects.[5] When compared to low-potency typical antipsychotics like chlorpromazine, Fluphenazine appears to have about equal overall effectiveness.[1] Comparative trials against several second-generation (atypical) antipsychotics, including amisulpride, risperidone, quetiapine, and olanzapine, have generally found no significant differences in improving the overall mental state or clinical response.[5] However, this body of evidence is limited by small trial sizes and is considered to be of low quality, and it does not account for potential differences in efficacy against negative or cognitive symptoms of schizophrenia.[7]

V. Dosage, Formulations, and Administration

This section provides practical, clinically-oriented guidance on the use of Fluphenazine, detailing its various formulations and the recommended protocols for their administration to ensure safety and efficacy.

Available Formulations

Fluphenazine is available in a variety of formulations to accommodate different clinical needs, from acute management to long-term maintenance therapy.

• Oral Formulations (as Hydrochloride salt):
• Tablets: Available in strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg.[2]
• Elixir: A liquid formulation with a concentration of 2.5 mg/5 mL.[8]
• Oral Concentrate: A high-concentration liquid (5 mg/mL) intended for dilution prior to administration.[8] The concentrate must be diluted in at least 60 mL (2 fluid ounces) of a suitable liquid such as milk, tomato juice, fruit juice, or uncaffeinated soft drinks. It should not be mixed with caffeinated beverages (e.g., coffee, cola), tea (which contains tannins), or apple juice (which contains pectinates), as these can cause precipitation of the drug.[8]
• Parenteral (Injectable) Formulations:
• Fluphenazine Hydrochloride (short-acting): Provided as a 2.5 mg/mL solution for intramuscular (IM) injection, used for the rapid control of acute psychotic symptoms.[8]
• Fluphenazine Decanoate (long-acting depot): A 25 mg/mL solution in a sesame oil vehicle for IM or subcutaneous (SC) administration, designed for maintenance therapy.[1] A 100 mg/mL concentration has also been available in some markets.[11]

Dosing and Titration

Dosage must be individualized based on the patient's clinical status, severity of symptoms, and tolerance.

• Oral (Adults):
• Initial Dose: The typical starting dosage is 2.5 to 10 mg per day, administered in divided doses every 6 to 8 hours.[2]
• Maintenance Dose: Once symptoms are controlled, the dosage is typically reduced to a maintenance level of 1 to 5 mg per day, which can often be given as a single daily dose.[8]
• Maximum Dose: While doses up to 40 mg per day may be used with caution in severely ill or inadequately controlled patients, therapeutic effects are often achieved with less than 20 mg per day. Doses above 20 mg/day are rarely more effective and are associated with a significantly higher burden of side effects.[22]
• Oral (Geriatric Patients): A lower starting dose of 1 to 2.5 mg per day in divided doses is recommended due to increased sensitivity to the drug's effects.[2]
• IM Hydrochloride (Short-Acting, Adults): For acute agitation, the initial dose is typically 1.25 mg IM. The total daily dosage can range from 2.5 to 10 mg, given in divided doses every 6 to 8 hours as needed.[2]
• IM/SC Decanoate (Long-Acting, Adults):
• Initial Dose: Therapy is typically initiated with a dose of 12.5 to 25 mg.[8]
• Maintenance Dose: Subsequent doses are adjusted based on patient response. Most patients are successfully maintained on a dose of 12.5 to 100 mg administered every 2 to 5 weeks, with a 3 to 4-week interval being most common.[20] The maximum dose should not exceed 100 mg per injection.[18]

Administration Guidelines

• Conversion from Oral to LAI: The transition from daily oral Fluphenazine HCl to the long-acting decanoate injection is a critical clinical procedure that requires careful calculation and monitoring. A widely cited approximate conversion ratio is that for every 10 mg of oral Fluphenazine HCl taken daily, an equivalent dose is 12.5 mg of Fluphenazine decanoate administered every 3 weeks.[8] It is imperative that patients are first stabilized on a short-acting formulation (oral or IM HCl) to establish their response, tolerance, and appropriate dosage level before being converted to the LAI formulation.[30]
• Injection Technique: The oil-based decanoate solution should be administered using a dry syringe and a needle of at least 21-gauge; moisture can cause the solution to appear cloudy.[8] The injection should be given deep intramuscularly into the gluteal region to ensure proper absorption and minimize local irritation.[8] Subcutaneous administration is also an approved route.[18]

A clear, consolidated table summarizing dosing information is an invaluable tool for clinicians, reducing the risk of error by presenting complex regimens in an easily digestible format.

Formulation	Population	Dosing Phase	Dose Range	Key Administration Notes
Oral (Tablets, Elixir, Concentrate)	Adult	Initial	2.5–10 mg/day, divided q6-8h	Concentrate must be diluted; avoid caffeine, tea, apple juice.
		Maintenance	1–5 mg/day, often as single dose	Doses >20 mg/day rarely more effective and poorly tolerated.
	Geriatric	Initial	1–2.5 mg/day, divided doses	Start low and titrate slowly due to increased sensitivity.
IM (Hydrochloride)	Adult	Acute	1.25 mg initial; up to 10 mg/day, divided q6-8h	For rapid control of acute agitation.
IM/SC (Decanoate)	Adult	Initial	12.5–25 mg	Patient must be stabilized on short-acting form first.
		Maintenance	12.5–100 mg, every 2-5 weeks	Max dose 100 mg. Administer deep IM into gluteal region.
		Conversion	12.5 mg LAI q3w ≈ 10 mg/day oral	This is an approximate ratio; individualize and monitor closely.

VI. Safety Profile and Tolerability

The safety profile of Fluphenazine is the primary factor limiting its use in modern clinical practice. Its propensity for severe neurological side effects necessitates careful patient selection, dosing, and vigilant monitoring.

Adverse Effects

• Extrapyramidal Symptoms (EPS): This class of movement disorders represents the most common and clinically defining side effect of Fluphenazine. As a high-potency typical antipsychotic, it has a strong tendency to produce EPS.[8] These symptoms include:
• Akathisia: A subjective feeling of inner restlessness and a compelling urge to be in constant motion, which can be extremely distressing for patients.[2]
• Parkinsonism: A syndrome mimicking Parkinson's disease, characterized by resting tremor, bradykinesia (slowness of movement), cogwheel rigidity, and a shuffling gait.[2]
• Acute Dystonia: Painful, involuntary, and sustained muscle spasms, which can affect various body parts. Common manifestations include torticollis (neck twisting), oculogyric crisis (forced upward deviation of the eyes), and laryngospasm, which can be a medical emergency.[2]
• Opisthotonos: A state of severe hyperextension and spasticity in which the individual's head, neck, and spinal column enter into a complete "bridging" or "arching" position.[2]
• Tardive Dyskinesia (TD): A potentially irreversible, hyperkinetic movement disorder that can emerge after long-term (months to years) of antipsychotic treatment.[1] It is characterized by involuntary, repetitive, choreoathetoid movements, most commonly affecting the orofacial region (e.g., lip-smacking, puckering, tongue protrusion, grimacing) but can also involve the limbs and trunk.[9] The risk of developing TD increases with the cumulative dose and duration of treatment.[9]
• Neuroleptic Malignant Syndrome (NMS): A rare but potentially fatal idiosyncratic reaction to antipsychotic drugs.[1] The cardinal features of NMS are hyperpyrexia (high fever), severe muscle rigidity ("lead-pipe" rigidity), altered mental status (from confusion to coma), and autonomic instability (e.g., irregular pulse, labile blood pressure, tachycardia, diaphoresis).[2] NMS requires immediate discontinuation of the offending agent and intensive supportive medical care.
• Autonomic and Anticholinergic Effects: These effects are generally weaker than those seen with low-potency phenothiazines but can still be troublesome.[8] They include dry mouth, blurred vision, constipation, urinary retention, and nasal congestion.[2]
• Cardiovascular Effects: Orthostatic hypotension, characterized by a drop in blood pressure upon standing that can cause dizziness or syncope, is a notable risk.[6] Tachycardia, hypertension, and fluctuations in blood pressure have also been reported.[20] Like other phenothiazines, Fluphenazine carries a risk of prolonging the QTc interval on the electrocardiogram (ECG), which can predispose patients to life-threatening ventricular arrhythmias such as Torsade de Pointes.[2]
• Endocrine and Metabolic Effects:
• Hyperprolactinemia: Potent D2 receptor blockade in the tuberoinfundibular pathway disrupts the tonic inhibition of prolactin secretion, leading to elevated serum prolactin levels.[2] This can manifest clinically as galactorrhea (inappropriate milk production), gynecomastia (breast enlargement in males), menstrual irregularities (oligomenorrhea or amenorrhea), and sexual dysfunction (e.g., impotence in men, anorgasmia).[1]
• Metabolic Changes: Weight gain is a common side effect.[1] Alterations in blood glucose levels and loss of diabetic control have also been reported.[32]
• Hepatic Effects: Mild and transient elevations in liver function tests (aminotransferases) can occur in up to 40% of patients on long-term phenothiazine therapy.[1] While usually benign, a more serious but rare adverse effect is cholestatic jaundice, which requires discontinuation of the drug.[32]
• Hematologic Effects: Rare but potentially fatal blood dyscrasias have been associated with Fluphenazine. These include leukopenia (low white blood cell count), agranulocytosis (a severe and dangerous leukopenia), and thrombocytopenia (low platelet count).[32]

Boxed Warning: Increased Mortality in Geriatric Patients with Dementia-Related Psychosis

• The Warning: The U.S. FDA has mandated a black-box warning for all antipsychotic drugs, including Fluphenazine, highlighting an increased risk of death when used to treat elderly patients with psychosis related to dementia.[2]
• The Evidence: This warning is based on analyses of multiple placebo-controlled trials which demonstrated a 1.6 to 1.7-fold increase in the risk of death in drug-treated patients compared to placebo.[9] The causes of death were varied but were primarily related to cardiovascular events (e.g., heart failure, sudden death) or infectious causes (e.g., pneumonia).[9]
• Clinical Implication: Fluphenazine is not approved for, and must not be used for, the treatment of dementia-related psychosis or behavioral disturbances in this patient population.[2]

Contraindications and Precautions

• Absolute Contraindications:
• Known hypersensitivity to Fluphenazine or a history of cross-sensitivity to other phenothiazine derivatives.[34]
• Use in comatose or severely depressed states.[9]
• Concurrent administration of large doses of central nervous system (CNS) depressants, such as hypnotics or alcohol.[18]
• Presence of suspected or established subcortical brain damage.[34]
• Pre-existing blood dyscrasia or severe liver damage.[18]
• Precautions (Use with Caution):
• In patients with a history of seizure disorders, as phenothiazines can lower the seizure threshold.[34]
• In patients with cardiovascular disease, narrow-angle glaucoma, prostatic hypertrophy, or renal/hepatic impairment.[34]
• In patients exposed to extreme heat or organophosphate insecticides, as phenothiazines can interfere with temperature regulation and potentiate toxicity, respectively.[18]
• In elderly or debilitated patients, who are more susceptible to hypotension and neuromuscular reactions.[43]

Use in Special Populations

• Pregnancy: The safety of Fluphenazine use during pregnancy has not been clearly established.[1] It is assigned Australian TGA Pregnancy Category C, indicating that it may have harmful pharmacological effects on the fetus without causing malformations.[1] Neonates exposed to antipsychotics during the third trimester of pregnancy are at risk for developing extrapyramidal and/or withdrawal symptoms following delivery, which may include agitation, tremor, respiratory distress, and feeding difficulties.[33] The medication should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus.[44]
• Lactation: There is no published experience with Fluphenazine during breastfeeding, and it is not known whether the drug is excreted into human milk.[38] Due to the potential for serious adverse reactions in the nursing infant, alternative antipsychotic agents are generally preferred, especially when nursing a newborn or preterm infant.[38]

VII. Drug Interactions

Fluphenazine is subject to a vast number of clinically significant drug interactions, estimated at over 700, due to its complex metabolism and its broad receptor-blocking profile.[46] These interactions can be categorized as either pharmacokinetic or pharmacodynamic.

Pharmacokinetic Interactions

• CYP2D6 Interactions: As a major substrate of the CYP2D6 enzyme, Fluphenazine's plasma concentrations can be significantly altered by co-administered drugs that inhibit or induce this isoenzyme.[2] Strong CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine, dacomitinib) can substantially increase Fluphenazine levels, heightening the risk of toxicity and severe adverse effects.[22] Conversely, CYP2D6 inducers (e.g., rifampin, carbamazepine) could potentially decrease its concentration, leading to a loss of efficacy.
• Absorption Interactions: Co-administration with antacids or antidiarrheals containing aluminum or magnesium (e.g., Almasilate) can decrease the gastrointestinal absorption of oral Fluphenazine, resulting in reduced serum concentrations and potentially a decrease in therapeutic efficacy.[4]

Pharmacodynamic Interactions

These interactions occur when drugs with additive or opposing effects at the receptor level are used concurrently.

• CNS Depressants: There is a major interaction with other CNS depressants. The co-administration of Fluphenazine with alcohol, benzodiazepines (e.g., alprazolam, lorazepam), opioids (e.g., benzhydrocodone), barbiturates, or sedating antihistamines results in additive CNS depression, which can manifest as profound sedation, cognitive impairment, and life-threatening respiratory depression.[4]
• Anticholinergic Agents: The concurrent use of drugs with significant anticholinergic properties, such as benztropine, tricyclic antidepressants (e.g., amitriptyline), or certain bladder antispasmodics, can lead to additive anticholinergic effects. This increases the risk of side effects such as severe constipation, urinary retention, blurred vision, cognitive impairment, and, in severe cases, paralytic ileus.[4]
• QTc-Prolonging Drugs: Co-administration of Fluphenazine with other medications known to prolong the QTc interval is highly risky and often contraindicated. Such drugs include certain antiarrhythmics (e.g., amiodarone, quinidine), macrolide antibiotics (e.g., clarithromycin), fluoroquinolone antibiotics, and many other antipsychotics (e.g., ziprasidone, chlorpromazine). The additive effect on QTc prolongation significantly increases the risk of Torsade de Pointes and sudden cardiac death.[37]
• Dopaminergic Agents: Fluphenazine, as a potent dopamine antagonist, directly opposes the mechanism of action of dopamine agonists. It will reduce or abolish the therapeutic efficacy of drugs used to treat Parkinson's disease, such as levodopa, bromocriptine, and apomorphine.[4]
• Adrenergic Agents: Fluphenazine can decrease the stimulatory effects of sympathomimetic agents like amphetamine.[4] Due to its alpha-adrenergic blocking properties, it can also interfere with the action of some antihypertensive medications and may potentiate hypotension.[43]

Lifestyle and Substance Interactions

• Alcohol: This is a major interaction. Alcohol potentiates the CNS depressant effects of Fluphenazine and should be strictly avoided.[20]
• Tobacco: This is also considered a major interaction. The polycyclic aromatic hydrocarbons in tobacco smoke are known inducers of hepatic enzymes, which can increase the metabolic clearance of phenothiazines. This may lead to lower plasma concentrations and reduced efficacy of Fluphenazine in heavy smokers.[43]
• Cannabis: A major interaction exists with cannabis, which can cause additive CNS depression, sedation, and cognitive impairment when used with Fluphenazine.[48]

Given the extensive list of potential interactions, a curated table focusing on the most clinically significant ones provides actionable guidance for prescribers.

Interacting Drug/Class	Mechanism/Effect	Severity	Clinical Recommendation
CNS Depressants (Alcohol, Benzodiazepines, Opioids)	Additive pharmacodynamic effect	Major	Avoid combination. Risk of profound sedation and respiratory depression.
QTc-Prolonging Agents (Amiodarone, Clarithromycin, Ziprasidone)	Additive effect on cardiac repolarization	Major	Avoid combination. Increased risk of life-threatening cardiac arrhythmias.
Dopamine Agonists (Levodopa, Bromocriptine)	Pharmacodynamic antagonism	Major	Avoid combination. Fluphenazine will block the therapeutic effect of the agonist.
CYP2D6 Inhibitors (Fluoxetine, Bupropion, Paroxetine)	Inhibition of metabolism	Major	Avoid or use with extreme caution. Monitor closely for Fluphenazine toxicity (EPS). Consider dose reduction.
Anticholinergic Agents (Benztropine, Amitriptyline)	Additive anticholinergic effects	Moderate	Monitor for constipation, urinary retention, blurred vision, and confusion.
Antacids (Aluminum/Magnesium Hydroxide)	Decreased oral absorption	Moderate	Separate administration times by at least 2 hours.
Tobacco Smoke	Induction of metabolism	Moderate	Be aware that efficacy may be reduced in smokers. Dose adjustments may be needed.

VIII. Comparative Analysis and Place in Therapy

This section critically evaluates Fluphenazine's position within the broader landscape of antipsychotic treatment, contextualizing its historical importance against its limited role in contemporary psychiatric practice.

Comparison with Other Antipsychotics

• Versus Low-Potency Typical Antipsychotics (e.g., Chlorpromazine): Fluphenazine is significantly more potent on a milligram-for-milligram basis than low-potency agents like chlorpromazine, but their overall clinical efficacy in treating psychosis is considered roughly equivalent.[1] The primary distinction lies in their side-effect profiles. As a high-potency agent, Fluphenazine has a much greater propensity to cause acute and chronic extrapyramidal symptoms (EPS). Conversely, chlorpromazine exhibits stronger antagonism at histaminic (H1), muscarinic (M1), and alpha-adrenergic (α1) receptors, resulting in significantly more sedation, anticholinergic side effects (dry mouth, constipation), and orthostatic hypotension.[5]
• Versus Second-Generation (Atypical) Antipsychotics (e.g., Olanzapine, Risperidone):
• Efficacy: The available evidence, though often of low quality and from small studies, suggests that there is no significant difference in efficacy for the positive symptoms of schizophrenia between Fluphenazine and several widely used atypical antipsychotics.[5] However, atypical agents are generally considered to have superior efficacy for the negative and cognitive symptoms of schizophrenia, although this advantage is modest.[2] A network meta-analysis found that Fluphenazine decanoate was more effective than chlorpromazine in preventing relapse and showed an intermediate efficacy that was not significantly different from many other agents.[50]
• Side Effects: The side-effect profile is the crucial differentiator and the primary reason for the shift in prescribing practices away from typical agents. Atypical antipsychotics are defined by their lower affinity for the D2 receptor relative to the 5-HT2A receptor, which is believed to confer a substantially lower risk of causing EPS and tardive dyskinesia.[2] This improved neurological tolerability is their main advantage. However, this benefit is offset by a different set of adverse effects. Many atypical agents, particularly olanzapine and clozapine, carry a much higher risk of inducing significant metabolic side effects, including substantial weight gain, dyslipidemia, insulin resistance, and new-onset type 2 diabetes.[50] Therefore, the choice between a typical agent like Fluphenazine and an atypical agent involves a critical trade-off between the risk of neurological side effects and the risk of metabolic side effects.

Historical Perspective and Current Role

Fluphenazine was first introduced in 1959 and, for several decades, was a cornerstone of pharmacotherapy for schizophrenia and other psychotic disorders.[1] Its development, along with other phenothiazines, revolutionized the treatment of severe mental illness and facilitated the process of deinstitutionalization.

However, since the introduction of the first atypical antipsychotics in the 1990s, the use of Fluphenazine and other typical agents has declined dramatically in developed countries.[2] This shift was driven almost entirely by the superior neurological tolerability of the newer drugs. Despite this decline, Fluphenazine retains a crucial, albeit small, place in modern therapy. Its primary niche is the use of its decanoate LAI formulation for the long-term maintenance treatment of patients with chronic schizophrenia who have a documented history of non-adherence to oral medications. For this specific population, the ensured delivery of medication via a depot injection can be life-stabilizing. Furthermore, as an inexpensive generic medication, it remains an important option in resource-limited settings and is included on the WHO's List of Essential Medicines.[1]

The lifecycle of Fluphenazine illustrates a complex interplay between clinical pharmacology, healthcare economics, and patient care. While newer, patent-protected atypical antipsychotics were heavily marketed based on their improved side-effect profiles, the inexpensive, off-patent Fluphenazine was largely superseded. The subsequent discontinuation of the drug in entire markets, such as Australia, reveals a critical post-market reality: a vulnerable population of patients with severe, chronic mental illness who had been successfully stabilized, sometimes for decades, on this "obsolete" drug were suddenly faced with forced medication changes.[1] This situation created a clinical crisis for these "legacy" patients, who often do not respond as well to or cannot tolerate newer agents, leading to a risk of psychotic decompensation and significant distress for both patients and their caregivers.[11] This scenario highlights a broader healthcare system challenge: how to balance the innovation and marketing of newer, "better" (and more profitable) medications with the long-term needs of specific patient populations who are stable and functional on older, effective, and cost-effective alternatives. It raises important questions about the ethical and clinical responsibilities of pharmaceutical companies and regulatory bodies to ensure continued access to essential, albeit less profitable, medicines.

IX. Regulatory Status

This section details the official standing of Fluphenazine with major regulatory bodies, providing a global perspective on its availability and legal status.

United States (FDA)

• Approval History: The original New Drug Application (NDA 011751) for the brand-name product Prolixin®, sponsored by Squibb, was first approved by the U.S. Food and Drug Administration on March 15, 1967.[3]
• Discontinuation of Brand: In October 2006, the NDA holder requested the withdrawal of Prolixin®. The FDA officially withdrew its approval for the brand-name product in March 2009.[52]
• Generic Availability: In August 2018, following a citizen petition, the FDA formally determined that Prolixin® was not withdrawn from the market for reasons of safety or effectiveness.[52] This critical determination cleared the path for the FDA to approve Abbreviated New Drug Applications (ANDAs) for generic versions of fluphenazine hydrochloride tablets. Consequently, generic formulations of Fluphenazine remain available in the United States.[1]
• Legal Status: Fluphenazine is a prescription-only medication (℞-only) in the U.S..[1]

Australia (TGA)

• Pregnancy Category: The Australian Therapeutic Goods Administration (TGA) assigned Fluphenazine to Pregnancy Category C.[1]
• Discontinuation: Fluphenazine was officially discontinued in Australia in 2017.[1] The registration for the brand Modecate® (fluphenazine decanoate) injection was formally cancelled by the sponsor, Bristol-Myers Squibb Australia, on March 21, 2018.[51] The manufacturer cited unpredictable supplies of the active pharmaceutical ingredient from the single global source as the reason for the discontinuation, explicitly stating it was not due to safety concerns.[11]
• Special Access Scheme: Despite its official discontinuation, anecdotal reports indicate that some patients who are critically dependent on the medication have been able to continue treatment through the TGA's Special Access Scheme. This scheme allows for the importation of unapproved therapeutic goods for specific patients, with reports of the product being sourced from countries such as India.[11]

Other Regions

• United Kingdom (UK): Fluphenazine is classified as a Prescription Only Medicine (POM).[1] While supplies were expected to be depleted by the end of 2018, some formulations may still be available.[11]
• Canada (CA): It is a prescription-only medication (℞-only).[1]
• Brazil (BR): Fluphenazine is classified as a Class C1 controlled substance.[1]
• World Health Organization (WHO): Recognizing its efficacy and importance for treating severe mental illness globally, the injectable form of Fluphenazine is included on the WHO's List of Essential Medicines.[1] This inclusion underscores its value, particularly in resource-limited healthcare systems where newer, more expensive alternatives may not be accessible.

X. Conclusion

Fluphenazine is a high-potency, first-generation phenothiazine antipsychotic with a long and significant history in the treatment of schizophrenia. Its potent dopamine D2 receptor antagonism provides robust efficacy against the positive symptoms of psychosis, an effect that remains comparable to many newer agents. However, this potent D2 blockade is also the source of its most significant limitation: a high propensity to cause debilitating acute and chronic extrapyramidal side effects, including the potentially irreversible condition of tardive dyskinesia.

The advent of atypical antipsychotics, with their more favorable neurological safety profiles, has rightly relegated Fluphenazine from a first-line therapy to a niche role in modern psychopharmacology. Its contemporary utility is now largely confined to its long-acting injectable decanoate formulation, which serves as an invaluable tool for ensuring medication adherence in patients with chronic schizophrenia who have previously demonstrated a good response and tolerance to the drug.

The clinical profile of Fluphenazine serves as a critical case study in the evolution of antipsychotic therapy, highlighting the paradigm shift from a focus solely on efficacy to a more balanced consideration of long-term safety and tolerability. The trade-off between the neurological risks of typical agents like Fluphenazine and the metabolic risks of many atypical agents remains a central challenge in the long-term management of schizophrenia. Furthermore, the discontinuation of Fluphenazine in some developed nations has exposed the profound clinical and ethical challenges that arise when legacy patients, long stabilized on an older, effective medication, are forced to transition to alternatives, underscoring the need for a healthcare system that supports the continued availability of essential, albeit less common, medicines. In conclusion, while its use has narrowed, Fluphenazine remains a clinically relevant medication for a specific patient population and an important chapter in the history of psychiatric medicine.

Works cited

1. Fluphenazine - Wikipedia, accessed November 3, 2025, https://en.wikipedia.org/wiki/Fluphenazine
2. Fluphenazine - StatPearls - NCBI Bookshelf, accessed November 3, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459194/
3. FLUPHENAZINE | 69-23-8 - ChemicalBook, accessed November 3, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7107784.htm
4. Fluphenazine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed November 3, 2025, https://go.drugbank.com/drugs/DB00623
5. Is Fluphenazine (a typical antipsychotic) a first-generation antipsychotic medication? - Dr.Oracle AI, accessed November 3, 2025, https://www.droracle.ai/articles/70595/fluphenazine-a-typical-antipsychotic-
6. What are the side effects of Fluphenazine Decanoate? - Patsnap Synapse, accessed November 3, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-fluphenazine-decanoate
7. Comparing effectiveness of an older antipsychotic (oral ... - Cochrane, accessed November 3, 2025, https://www.cochrane.org/evidence/CD010832_comparing-effectiveness-older-antipsychotic-oral-fluphenazine-newer-antipsychotics-treating
8. Fluphenazine: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed November 3, 2025, https://www.medcentral.com/drugs/monograph/5044-382172/fluphenazine-oral
9. Fluphenazine Oral Solution: Package Insert / Prescribing Info, accessed November 3, 2025, https://www.drugs.com/pro/fluphenazine-oral-solution.html
10. Fluphenazine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed November 3, 2025, https://www.rxlist.com/fluphenazine/generic-drug.htm
11. Fluphenazine decanoate discontinued - Prescribing Advice for GPs, accessed November 3, 2025, https://www.prescriber.org.uk/2017/06/fluphenazine-decanoate-discontinued/
12. www.ncbi.nlm.nih.gov, accessed November 3, 2025, https://www.ncbi.nlm.nih.gov/books/NBK582713/#:~:text=Fluphenazine%20is%20a%20medication%20that,Prolixin%C2%AE%20and%20Permitil%C2%AE.
13. Fluphenazine - brand name list from Drugs.com, accessed November 3, 2025, https://www.drugs.com/ingredient/fluphenazine.html
14. Antipsychotic Medications: What They Are, Uses & Side Effects - Cleveland Clinic, accessed November 3, 2025, https://my.clevelandclinic.org/health/treatments/24692-antipsychotic-medications
15. fluphenazine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed November 3, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=204
16. Fluphenazine | C22H26F3N3OS | CID 3372 - PubChem, accessed November 3, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Fluphenazine
17. Fluphenazine | 69-23-8 | FF102008 - Biosynth, accessed November 3, 2025, https://www.biosynth.com/p/FF102008/69-23-8-fluphenazine
18. FLUPHENAZINE DECANOATE - accessdata.fda.gov, accessed November 3, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/071413s019lbl.pdf
19. Fluphenazine decanoate | DrugBank Online, accessed November 3, 2025, https://go.drugbank.com/salts/DBSALT000776
20. Fluphenazine decanoate - FDA Verification Portal, accessed November 3, 2025, https://verification.fda.gov.ph/files/DR-XY44239_PI_01.pdf
21. Fluphenazine (dose) for people with schizophrenia - PMC - NIH, accessed November 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6485658/
22. FLUPHENAZINE (Prolixin) Fact Sheet [G] - Medication Fact Book for Psychiatric Practice, 7th Edition, accessed November 3, 2025, https://www.thecarlatreport.com/ext/resources/factsheets/MFB7e/FLUPHENAZINE\-(Prolixin)\-Fact\-Sheet\-\[G].pdf?t\=1701963339
23. Fluphenazine Tablets: Package Insert / Prescribing Info - Drugs.com, accessed November 3, 2025, https://www.drugs.com/pro/fluphenazine-tablets.html
24. Fluphenazine - Prescriber's Guide – Children and Adolescents, accessed November 3, 2025, https://www.cambridge.org/core/books/prescribers-guide-children-and-adolescents/fluphenazine/ECE83823B629ACB3764E881F9BEB77ED
25. www.medicinenet.com, accessed November 3, 2025, https://www.medicinenet.com/fluphenazine/article.htm#:~:text=Fluphenazine%20is%20used%20off%2Dlabel,unintended%20sounds%20(phonic%20tics).
26. Fluphenazine Alternatives Compared - Drugs.com, accessed November 3, 2025, https://www.drugs.com/compare/fluphenazine
27. Fluphenazine Completed Phase 2 Trials for Psoriasis Treatment | DrugBank Online, accessed November 3, 2025, https://go.drugbank.com/drugs/DB00623/clinical_trials?conditions=DBCOND0013339&phase=2&purpose=treatment&status=completed
28. Fluphenazine Completed Phase N/A Trials for Schizophrenia | DrugBank Online, accessed November 3, 2025, https://go.drugbank.com/drugs/DB00623/clinical_trials?conditions=DBCOND0018504&status=completed
29. Fluphenazine Completed Phase N/A Trials for Bipolar Disorder (BD) / Schizoaffective Disorders / Type 2 Diabetes Mellitus / Schizophrenia / Psychosis - DrugBank, accessed November 3, 2025, https://go.drugbank.com/drugs/DB00623/clinical_trials?conditions=DBCOND0034367%2CDBCOND0020753%2CDBCOND0033299%2CDBCOND0018504%2CDBCOND0029752&status=completed
30. Fluphenazine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed November 3, 2025, https://www.drugs.com/dosage/fluphenazine.html
31. Fluphenazine - FPnotebook, accessed November 3, 2025, https://fpnotebook.com/Psych/Pharm/Flphnzn.htm
32. Fluphenazine Side Effects: Common, Severe, Long Term - Drugs.com, accessed November 3, 2025, https://www.drugs.com/sfx/fluphenazine-side-effects.html
33. Fluphenazine | National Alliance on Mental Illness (NAMI), accessed November 3, 2025, https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/fluphenazine/
34. FluPHENAZine Monograph for Professionals - Drugs.com, accessed November 3, 2025, https://www.drugs.com/monograph/fluphenazine.html
35. Fluphenazine: Uses, Side Effects, Dosage & More - GoodRx, accessed November 3, 2025, https://www.goodrx.com/fluphenazine/what-is
36. Fluphenazine (Prolixin): Uses & Side Effects - Cleveland Clinic, accessed November 3, 2025, https://my.clevelandclinic.org/health/drugs/20254-fluphenazine-tablets
37. Modecate, Modecate Concentrate (fluphenazine) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed November 3, 2025, https://reference.medscape.com/drug/fluphenazine-342973
38. Fluphenazine - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf - NIH, accessed November 3, 2025, https://www.ncbi.nlm.nih.gov/books/NBK500732/
39. Fluphenazine - LiverTox - NCBI Bookshelf - NIH, accessed November 3, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548610/
40. Jacoby & Meyers | Dangerous Drugs | Fluphenazine, accessed November 3, 2025, https://dangerousdrugs.com/drug-black-box-warnings/fluphenazine/
41. fluphenazine decanoate: Dosing, contraindications, side effects, and pill pictures - Epocrates, accessed November 3, 2025, https://www.epocrates.com/online/drugs/4107/fluphenazine-decanoate
42. Fluphenazine: Schizophrenia Uses, Warnings, Side Effects, Dosage - MedicineNet, accessed November 3, 2025, https://www.medicinenet.com/fluphenazine/article.htm
43. fluphenazine decanoate, accessed November 3, 2025, https://glowm.com/resources/glowm/cd/pages/drugs/f029.html
44. Fluphenazine Use During Pregnancy - Drugs.com, accessed November 3, 2025, https://www.drugs.com/pregnancy/fluphenazine.html
45. Fluphenazine (Prolixin®, Permitil®) - MotherToBaby | Fact Sheets - NCBI - NIH, accessed November 3, 2025, https://www.ncbi.nlm.nih.gov/books/NBK582713/
46. Fluphenazine Interactions Checker - Drugs.com, accessed November 3, 2025, https://www.drugs.com/drug-interactions/fluphenazine.html
47. Prolixin Interactions Checker - Drugs.com, accessed November 3, 2025, https://www.drugs.com/drug-interactions/fluphenazine,prolixin.html
48. Fluphenazine Decanoate Food, Alcohol, Supplements and Drug Interactions, accessed November 3, 2025, https://www.wellrx.com/fluphenazine-decanoate/lifestyle-interactions/
49. Drug Interactions for Fluphenazine Hydrochloride - Prescriber Point, accessed November 3, 2025, https://prescriberpoint.com/therapies/fluphenazine-hydrochloride-b6eadd5/interactions
50. Long-term antipsychotic treatment in schizophrenia: systematicreview and network meta-analysis of randomised controlledtrials | BJPsych Open, accessed November 3, 2025, https://www.cambridge.org/core/journals/bjpsych-open/article/longterm-antipsychotic-treatment-in-schizophrenia-systematic-review-and-network-metaanalysis-of-randomised-controlled-trials/071CED994231A1D83237B334F71FB6C4
51. MODECATE fluphenazine decanoate 12.5mg/0.5mL injection ampoule Cancelled under s30(1)(c) | Therapeutic Goods Administration (TGA), accessed November 3, 2025, https://www.tga.gov.au/resources/cancellations-by-sponsors/modecate-fluphenazine-decanoate-125mg05ml-injection-ampoule-cancelled-under-s301c
52. Determination That PROLIXIN (Fluphenazine ... - Federal Register, accessed November 3, 2025, https://www.federalregister.gov/documents/2018/08/09/2018-17026/determination-that-prolixin-fluphenazine-hydrochloride-tablets-1-milligram-25-milligrams-5